ArticleCancer immunology, immunotherapy : CII2023
Safety and efficacy of the anti-PD1 immunotherapy with nivolumab in trichoblastic carcinomas.
E Toulemonde et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this paperpooled itcites it